With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
The Drug Resistance Working Group is focusing on the potential for solutions effected collectively or individually by organizations that operate at the global level. The Group draws on the strength of its diverse composition to extend the problem-solving conversation around drug resistance into and among communities that all have an interest, but rarely have the opportunity to forge joint solutions. In doing so, members stimulate each other’s active commitment to address the problem, possibly through changes in funding, policies and program implementation.
The main product of the Working Group will be a policy report identifying practical and feasible actions (anticipated in Spring 2010). The report will include recommendations for the global donor community, outlining the responsibilities different actors should bear, while pointing out opportunities and needs at the local, national, and intra-institutional levels. The findings will be disseminated to decision-makers in key development and funding organizations, as well as key private sector interests, through targeted briefings, events, and outreach.
Membership & Composition
The Drug Resistance Working Group is chaired by Rachel Nugent of the Center for Global Development under the auspices of CGD's Global Health Policy Research Network. Support is provided by the Bill & Melinda Gates Foundation. Members of the Working Group were invited to join in a personal capacity and on a voluntary basis, and include experts from the pharmaceutical industry, public health sectors in developing and developed countries, technical and funding agencies, product development partnerships, advocacy organizations and academia.
Rachel Nugent, Center for Global Development
Emma Back, independent consultant
Ted Bianco, Wellcome Trust
Nancy Blum, independent consultant
Joanne Carter, RESULTS Educational Fund
Gail Cassell, Eli Lilly and Company
John Chalker, Management Sciences for Health
Alexander Dodoo, University of Ghana Medical School
Dai Ellis, Clinton Foundation HIV/AIDS Initiative
Susan Foster, Alliance for the Prudent Use of Antibiotics
Fred Goldberg, Saltchuk Resources Inc.
Martha Gyansa-Lutterodt, Ghana National Drugs Programme
Jerry Keusch, Boston University School of Public Health
Ruth Levine, Center for Global Development
Paul Nunn, World Health Organization/Stop TB
Iruka Okeke, Haverford College
Kevin Outterson, Boston University School of Law
Mead Over, Center for Global Development
Eddie Power, Schering-Plough
Andrew Ramsay, World Health Organization/Special Programme for Research and Training in Tropical Diseases
Renee Ridzon, Bill & Melinda Gates Foundation
David Roos, University of Pennsylvania
Harvey Rubin, University of Pennsylvania
Carol Sibley, University of Washington
Suniti Solomon, Y.R. Gaitonde Center for AIDS Research & Education
Walter Straus, Merck Vaccines and Infectious Diseases
Thelma Tupasi, Tropical Disease Foundation
Saul Walker, UK Department for International Development
Nicholas White, Mahidol University
Prashant Yadav, MIT-Zaragoza International Logistics Program